Bon Secours Mercy Health Nears $6 Billion Acquisition of Surgery Partners

The Quick Take

• Bon Secours Mercy Health is nearing a $6 billion acquisition of Surgery Partners (SGRY), which would be one of the largest healthcare M&A deals of 2026.
• The deal would give the not-for-profit hospital system ownership of Surgery Partners' ambulatory surgery center (ASC) network across the US.
• SGRY shareholders stand to receive a significant premium, with the stock likely re-rating sharply on deal confirmation.

Synthesized from 1 source.

Bon Secours Mercy Health, one of the largest not-for-profit hospital systems in the United States, is reportedly nearing a $6 billion deal to acquire Surgery Partners (SGRY), a publicly traded operator of ambulatory surgery centers and surgical facilities. The proposed transaction would represent a major consolidation move in the US healthcare sector, reflecting a structural trend of large hospital systems acquiring ASC networks to capture outpatient surgical volumes that have been migrating away from high-cost inpatient settings. If completed, the deal would substantially expand Bon Secours' outpatient surgical footprint.

The $6 billion price tag carries significant implications for SGRY shareholders and healthcare sector valuations more broadly. Surgery Partners' stock will trade toward the offer price, representing a premium to its pre-announcement levels. Hospital system peers that own ASC platforms — including HCA Healthcare, Tenet Health, and United Surgical Partners — could see valuation recalibration as the deal signals strong M&A demand for ASC assets. Private equity-backed ASC platform operators may also see bid activity increase as strategic acquirers compete for high-quality ambulatory surgery assets.

Key signals to watch include formal deal announcement with terms, regulatory clearance from the FTC given recent scrutiny of healthcare provider consolidation, and Surgery Partners' Q3 earnings commentary on the strategic review process. The macro variable is the interest rate environment: at $6 billion, Bon Secours would likely take on significant debt financing, making the deal's economics sensitive to borrowing costs and the credit market's appetite for healthcare M&A paper in the current rate cycle.